Phreesia (PHR) 10-Q 5 Sep 24 2025 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jul. 31, 2024	Aug. 29, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 31, 2024
Document Transition Report	false
Entity File Number	001-38977
Entity Registrant Name	PHREESIA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2275479
Entity Address, Address Line One	1521 Concord Pike
Entity Address, Address Line Two	Suite 301 PMB 221
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19803
City Area Code	888
Local Phone Number	654-7473
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	PHR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		57,773,275
Amendment Flag	false
Entity Central Index Key	0001412408
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--01-31

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Current:
Cash and cash equivalents	$ 81,798	$ 87,520
Settlement assets	25,320	28,072
Accounts receivable, net of allowance for doubtful accounts of $1,365 and $1,392 as of July 31, 2024 and January 31, 2024, respectively	61,274	64,863
Deferred contract acquisition costs	841	768
Prepaid expenses and other current assets	11,695	14,461
Total current assets	180,928	195,684
Property and equipment, net of accumulated depreciation and amortization of $84,295 and $76,859 as of July 31, 2024 and January 31, 2024, respectively	20,955	16,902
Capitalized internal-use software, net of accumulated amortization of $50,559 and $45,769 as of July 31, 2024 and January 31, 2024, respectively	49,767	46,139
Operating lease right-of-use assets	1,863	266
Deferred contract acquisition costs	742	986
Intangible assets, net of accumulated amortization of $6,666 and $4,925 as of July 31, 2024 and January 31, 2024, respectively	29,884	31,625
Goodwill	75,845	75,845
Other assets	2,251	2,879
Total Assets	362,235	370,326
Current:
Settlement obligations	25,320	28,072
Current portion of finance lease liabilities and other debt	7,161	6,056
Current portion of operating lease liabilities	989	393
Accounts payable	6,976	8,480
Accrued expenses	32,668	37,130
Deferred revenue	21,370	24,113
Other current liabilities	7,515	5,875
Total current liabilities	101,999	110,119
Long-term finance lease liabilities and other debt	7,297	5,400
Operating lease liabilities, non-current	1,075	134
Long-term deferred revenue	63	97
Long-term deferred tax liabilities	390	270
Other long-term liabilities	76	2,857
Total Liabilities	110,900	118,877
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Preferred stock, undesignated, $0.01 par value—$20,000,000 shares authorized as of both July 31, 2024 and January 31, 2024; no shares issued or outstanding as of both July 31, 2024 and January 31, 2024	0	0
Common stock, $0.01 par value - 500,000,000 shares authorized as of both July 31, 2024 and January 31, 2024; 59,057,170 and 57,709,762 shares issued as of July 31, 2024 and January 31, 2024, respectively	591	577
Additional paid-in capital	1,076,969	1,039,361
Accumulated deficit	(780,703)	(742,969)
Accumulated other comprehensive loss	(2)	0
Treasury stock, at cost, 1,355,169 shares as of both July 31, 2024 and January 31, 2024	(45,520)	(45,520)
Total Stockholders’ Equity	251,335	251,449
Total Liabilities and Stockholders’ Equity	$ 362,235	$ 370,326

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 1,365	$ 1,392
Accumulated depreciation and amortization, property and equipment	84,295	76,859
Accumulated amortization, capitalized internal-use software	50,559	45,769
Accumulated amortization, intangible assets	$ 6,666	$ 4,925
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	500,000,000	500,000,000
Common stock, issued (in shares)	59,057,170	57,709,762
Treasury stock (in shares)	1,355,169	1,355,169

Unaudited Consolidated Statemen

Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Revenue:
Total revenues	$ 102,115	$ 85,830	$ 203,332	$ 169,675
Expenses:
Cost of revenue (excluding depreciation and amortization)	16,143	14,449	31,866	29,356
Payment processing expense	16,668	15,852	34,965	31,942
Sales and marketing	30,184	37,244	62,195	74,657
Research and development	29,542	27,471	58,423	53,940
General and administrative	19,497	20,988	38,549	40,865
Depreciation	3,921	4,244	7,445	8,748
Amortization	3,382	2,537	6,531	5,023
Total expenses	119,337	122,785	239,974	244,531
Operating loss	(17,222)	(36,955)	(36,642)	(74,856)
Other (expense) income, net	(86)	50	(117)	8
Interest income, net	46	786	285	1,504
Total other (expense) income, net	(40)	836	168	1,512
Loss before provision for income taxes	(17,262)	(36,119)	(36,474)	(73,344)
Provision for income taxes	(750)	(648)	(1,260)	(954)
Net loss	$ (18,012)	$ (36,767)	$ (37,734)	$ (74,298)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.31)	$ (0.68)	$ (0.66)	$ (1.39)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.31)	$ (0.68)	$ (0.66)	$ (1.39)
Weighted-average common shares outstanding, basic (in shares)	57,502,959	53,794,060	57,089,232	53,574,584
Weighted-average common shares outstanding, diluted (in shares)	57,502,959	53,794,060	57,089,232	53,574,584
Subscription and related services
Revenue:
Total revenues	$ 48,612	$ 39,301	$ 95,354	$ 77,188
Payment processing fees
Revenue:
Total revenues	25,300	23,631	52,360	47,884
Network solutions
Revenue:
Total revenues	$ 28,203	$ 22,898	$ 55,618	$ 44,603

Unaudited Consolidated Statem_2

Unaudited Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (18,012)	$ (36,767)	$ (37,734)	$ (74,298)
Other comprehensive loss, net of tax:
Change in foreign currency translation adjustments, net of tax	(3)	0	(2)	0
Other comprehensive loss, net of tax	(3)	0	(2)	0
Comprehensive loss	$ (18,015)	$ (36,767)	$ (37,736)	$ (74,298)

Unaudited Consolidated Statem_3

Unaudited Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	APIC	Accumulated Deficit	Accumulated other comprehensive loss	Treasury stock
Beginning balance (in shares) at Jan. 31, 2023		54,187,172
Beginning balance at Jan. 31, 2023	$ 287,819	$ 542	$ 926,957	$ (606,084)	$ 0	$ (33,596)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(37,531)			(37,531)
Stock-based compensation	14,950		14,950
Exercise of stock options and vesting of restricted stock units (in shares)		404,012
Exercise of stock options and vesting of restricted stock units	155	$ 4	151
Issuance of stock for share-settled bonus awards (in shares)		175,688
Issuance of stock for share-settled bonus awards	5,297	$ 2	5,295
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	(7,079)					(7,079)
Ending balance (in shares) at Apr. 30, 2023		54,766,872
Ending balance at Apr. 30, 2023	263,611	$ 548	947,353	(643,615)	0	(40,675)
Beginning balance (in shares) at Jan. 31, 2023		54,187,172
Beginning balance at Jan. 31, 2023	287,819	$ 542	926,957	(606,084)	0	(33,596)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(74,298)
Ending balance (in shares) at Jul. 31, 2023		55,364,795
Ending balance at Jul. 31, 2023	247,020	$ 554	971,120	(680,382)	0	(44,272)
Beginning balance (in shares) at Apr. 30, 2023		54,766,872
Beginning balance at Apr. 30, 2023	263,611	$ 548	947,353	(643,615)	0	(40,675)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(36,767)			(36,767)
Stock-based compensation	16,747		16,747
Exercise of stock options and vesting of restricted stock units (in shares)		374,128
Exercise of stock options and vesting of restricted stock units	426	$ 3	423
Issuance of stock for share-settled bonus awards (in shares)		2,886
Issuance of stock for share-settled bonus awards	86		86
Issuance of common stock for employee stock purchase plan (in shares)		70,123
Issuance of common stock for employee stock purchase plan	1,838	$ 1	1,837
Issuance of common stock as consideration in business combinations (in shares)		150,786
Issuance of common stock as consideration in business combinations	4,676	$ 2	4,674
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	(3,597)					(3,597)
Ending balance (in shares) at Jul. 31, 2023		55,364,795
Ending balance at Jul. 31, 2023	$ 247,020	$ 554	971,120	(680,382)	0	(44,272)
Beginning balance (in shares) at Jan. 31, 2024	57,709,762	57,709,762
Beginning balance at Jan. 31, 2024	$ 251,449	$ 577	1,039,361	(742,969)	0	(45,520)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(19,722)			(19,722)
Other comprehensive income (loss)	1				1
Stock-based compensation	14,491		14,491
Exercise of stock options and vesting of restricted stock units (in shares)		718,340
Exercise of stock options and vesting of restricted stock units	346	$ 7	339
Issuance of stock for share-settled bonus awards (in shares)		283,354
Issuance of stock for share-settled bonus awards	6,177	$ 3	6,174
Ending balance (in shares) at Apr. 30, 2024		58,711,456
Ending balance at Apr. 30, 2024	$ 252,742	$ 587	1,060,365	(762,691)	1	(45,520)
Beginning balance (in shares) at Jan. 31, 2024	57,709,762	57,709,762
Beginning balance at Jan. 31, 2024	$ 251,449	$ 577	1,039,361	(742,969)	0	(45,520)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (37,734)
Other comprehensive income (loss)					(2)
Exercise of stock options and vesting of restricted stock units (in shares)	118,153
Issuance of common stock for employee stock purchase plan (in shares)		89,220
Ending balance (in shares) at Jul. 31, 2024	59,057,170	59,057,170
Ending balance at Jul. 31, 2024	$ 251,335	$ 591	1,076,969	(780,703)	(2)	(45,520)
Beginning balance (in shares) at Apr. 30, 2024		58,711,456
Beginning balance at Apr. 30, 2024	252,742	$ 587	1,060,365	(762,691)	1	(45,520)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(18,012)			(18,012)
Other comprehensive income (loss)	(3)				(3)
Stock-based compensation	14,739		14,739
Exercise of stock options and vesting of restricted stock units (in shares)		254,569
Exercise of stock options and vesting of restricted stock units	220	$ 3	217
Issuance of stock for share-settled bonus awards (in shares)		1,925
Issuance of stock for share-settled bonus awards	41		41
Issuance of common stock for employee stock purchase plan (in shares)		89,220
Issuance of common stock for employee stock purchase plan	$ 1,608	$ 1	1,607
Ending balance (in shares) at Jul. 31, 2024	59,057,170	59,057,170
Ending balance at Jul. 31, 2024	$ 251,335	$ 591	$ 1,076,969	$ (780,703)	$ (2)	$ (45,520)

Unaudited Consolidated Statem_4

Unaudited Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Operating activities:
Net loss	$ (18,012)	$ (36,767)	$ (37,734)	$ (74,298)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	7,303	6,781	13,976	13,771
Stock-based compensation expense	16,448	18,648	33,288	35,786
Amortization of deferred financing costs and debt discount	51	84	112	169
Cost of Phreesia hardware purchased by customers	334	234	677	650
Deferred contract acquisition costs amortization	192	280	384	620
Non-cash operating lease expense	188	109	361	342
Deferred taxes	56	(75)	119	142
Changes in operating assets and liabilities:
Accounts receivable	4,976	(832)	3,583	(2,370)
Prepaid expenses and other assets	2,867	(383)	3,281	769
Deferred contract acquisition costs	(213)	0	(213)	0
Accounts payable	1,186	568	(1,750)	(2,415)
Accrued expenses and other liabilities	(1,392)	4,239	(2,547)	6,061
Lease liabilities	(201)	(405)	(420)	(652)
Deferred revenue	(2,722)	(1,812)	(2,777)	(1,565)
Net cash provided by (used in) operating activities	11,061	(9,331)	10,340	(22,990)
Investing activities:
Acquisitions, net of cash acquired	0	(3,873)	0	(3,873)
Capitalized internal-use software	(2,976)	(5,088)	(7,546)	(9,820)
Purchases of property and equipment	(4,427)	(755)	(5,303)	(2,102)
Net cash used in investing activities	(7,403)	(9,716)	(12,849)	(15,795)
Financing activities:
Proceeds from issuance of common stock upon exercise of stock options	219	426	566	675
Treasury stock to satisfy tax withholdings on stock compensation awards	0	(3,775)	0	(10,725)
Proceeds from employee stock purchase plan	690	896	1,603	1,863
Finance lease payments	(1,995)	(1,983)	(3,275)	(3,427)
Constructive financing	0	1,688	0	1,688
Principal payments on financing agreements	(295)	(45)	(584)	(45)
Debt issuance costs and loan facility fee payments	0	(250)	(152)	(250)
Financing payments of acquisition-related liabilities	0	0	(1,364)	0
Net cash used in financing activities	(1,381)	(3,043)	(3,206)	(10,221)
Effect of exchange rate changes on cash and cash equivalents	(6)	0	(7)	0
Net increase (decrease) in cash and cash equivalents	2,271	(22,090)	(5,722)	(49,006)
Cash and cash equivalents – beginning of period	79,527	149,767	87,520	176,683
Cash and cash equivalents – end of period	81,798	127,677	81,798	127,677
Supplemental information of non-cash investing and financing information:
Right of use assets acquired in exchange for operating lease liabilities	1,194	0	1,958	0
Property and equipment acquisitions through finance leases	333	0	6,862	7,067
Purchase of property and equipment and capitalized software included in current liabilities	1,517	1,509	1,517	1,509
Capitalized stock-based compensation	315	377	663	714
Issuance of stock to settle liabilities for stock-based compensation	1,649	1,924	7,826	7,221
Issuance of stock as consideration in business combinations	0	4,676	0	4,676
Issuance of liabilities as consideration in business combinations	0	91	0	91
Capitalized software acquired through vendor financing	0	2,047	0	2,047
Cash paid for:
Interest	381	296	864	354
Income taxes	$ 417	$ 13	$ 2,010	$ 53

Background and liquidity

Background and liquidity	6 Months Ended
	Jul. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	Background and liquidity (a) Background Phreesia, Inc. (the "Company") is a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations and improve health outcomes by helping patients take a more active role in their care. The Company’s solutions include SaaS-based integrated tools that manage patient access, registration and payments. Additionally, the Company has tools to communicate with patients about their health and have demonstrated increased rates of preventive care and vaccinations. Additionally, Phreesia's solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to better understand their patients and connect them to needed services, resulting in improved health outcomes. The Company also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. Phreesia’s solutions also include additional products and services such as the MediFind provider directory, which helps patients find care based on providers’ specific clinical expertise. Phreesia offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription. The Company was formed in May 2005. (b) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that net losses and negative cash flows will continue for at least the next year. Management believes that the Company’s cash and cash equivalents at July 31, 2024, along with cash generated in the normal course of business and available borrowing capacity under its revolving credit facility with Capital One (the “Capital One Credit Facility”), are sufficient to fund its operations for at least the next 12 months. The Company may seek to obtain additional financing, if needed, to successfully implement its long-term strategy.

Basis of presentation

Basis of presentation	6 Months Ended
	Jul. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation (a) Consolidated financial statements The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding quarterly financial reporting and include the accounts of Phreesia, Inc., its branch operation in Canada and its consolidated subsidiaries (or collectively, the "Company"). (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2025 and 2024 refer to the fiscal years ending on January 31, 2025 and January 31, 2024, respectively. (c) Unaudited interim financial statements The accompanying unaudited interim consolidated financial statements have been prepared in accordance with GAAP and applicable rules and regulations of the SEC regarding interim financial reporting. In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s interim financial position as of July 31, 2024 and the results of its operations, changes in its stockholders' equity and its cash flows for the periods ended July 31, 2024 and 2023. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The results for the interim periods are not necessarily indicative of results to be expected for the full year, any other interim periods, or any future year or period. The Company’s management believes that the disclosures herein are adequate to make the information presented not misleading when read in conjunction with the audited financial statements and accompanying notes for the fiscal year ended January 31, 2024.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jul. 31, 2024
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies The Company’s significant accounting policies are disclosed in the audited financial statements for the fiscal year ended January 31, 2024. Since the date of those audited financial statements, there have been no material changes to the Company’s significant accounting policies, including the status of recent accounting pronouncements, other than those detailed below. (a) Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other market-specific factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results could differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets. (b) Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the three months ended July 31, 2024 and 2023. As of both July 31, 2024 and January 31, 2024, the Company had receivables from at least one entity that accounted for at least 10% of total accounts receivable. (c) Risks and uncertainties The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. The Company supplements its workforce with contractors and consultants, including a substantial number of contractors and consultants in international locations. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. (d) Foreign currency The functional currency of the Company’s subsidiaries and branch in the U.S. and Canada is the US Dollar. The functional currency of the Company’s subsidiary in India is the Indian Rupee. For subsidiaries with functional currencies other than the US Dollar, the Company translates the functional currency financial statements into US Dollars using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign currency translation adjustments are recorded as accumulated other comprehensive loss within stockholders’ equity in the Company’s consolidated balance sheets. Foreign currency transaction gains and losses to re-measure monetary assets and liabilities into each entity’s functional currency are included in Other (expense) income, net. (e) New accounting pronouncements Impact of recently adopted accounting pronouncements During the three and six months ended July 31, 2024, the Company did not adopt any accounting pronouncements that materially impacted the Company's financial statements. Recent accounting pronouncements not yet adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting. The new standard requires enhanced disclosures about significant segment expenses and other segment items and requires companies to disclose all annual disclosures about segments in interim periods. The new standard also permits companies to disclose more than one measure of segment profit or loss, requires disclosure of the title and position of the Chief Operating Decision Maker, and requires companies with a single reportable segment to provide all disclosures required by Topic 280 – Segment Reporting. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Companies are required to apply ASU 2023-07 retrospectively to all periods presented. The Company is currently evaluating the impact that ASU 2023-07 will have on its financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024; early adoption is permitted for annual statements. The Company is currently evaluating the impact that ASU 2023-09 will have on its financial statements and related disclosures. There are no other recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.

Composition of certain financia

Composition of certain financial statement captions	6 Months Ended
	Jul. 31, 2024
Composition of Certain Financial Statements [Abstract]
Composition of certain financial statement captions	Composition of certain financial statement captions (a) Accrued expenses Accrued expenses as of July 31, 2024 and January 31, 2024 are as follows: July 31, 2024 January 31, 2024 Payroll-related expenses and taxes $ 11,664 $ 8,981 Stock-based compensation liability 4,393 5,890 Payment processing fees liability 5,517 6,008 Acquisition-related liabilities 997 1,888 Income and other tax liabilities 2,005 3,042 Information technology 4,971 5,927 Other 3,121 5,394 Total $ 32,668 $ 37,130 (b) Other current liabilities and other long-term liabilities Other current liabilities as of July 31, 2024 and January 31, 2024 were $7,515 and $5,875, respectively. Other long-term liabilities as of July 31, 2024 and January 31, 2024 were $76 and $2,857, respectively. Other current liabilities and other long-term liabilities primarily represent deferred consideration liabilities payable to the former equity holders of ConnectOnCall.com, LLC (“ConnectOnCall”) which the Company acquired during the year ended January 31, 2024. Deferred consideration liabilities are payable through June 30, 2025. Accordingly, as of July 31, 2024, all deferred consideration liabilities are classified as other current liabilities. (c) Property and equipment Property and equipment as of July 31, 2024 and January 31, 2024 are as follows: Useful Life (years) July 31, 2024 January 31, 2024 PhreesiaPads and Arrivals Kiosks 3 $ 20,858 $ 18,610 Computer equipment 3 70,250 62,888 Computer software 3 to 5 13,567 11,687 Hardware development 3 575 576 Total property and equipment $ 105,250 $ 93,761 Less: accumulated depreciation (84,295) (76,859) Property and equipment — net $ 20,955 $ 16,902 Depreciation expense related to property and equipment amounted to $3,921 and $4,244 for the three months ended July 31, 2024 and 2023, respectively. Depreciation expense related to property and equipment amounted to $7,445 and $8,748 for the six months ended July 31, 2024 and 2023, respectively. Property and equipment - net and related depreciation expense includes assets acquired under finance leases. Assets acquired under finance leases included in computer equipment were $42,112 and $35,250 as of July 31, 2024 and January 31, 2024, respectively. Accumulated amortization of assets under finance leases was $30,777 and $27,399 as of July 31, 2024 and January 31, 2024, respectively. See Note 10 - Leases for additional information regarding finance leases. (d) Capitalized internal use software For the three months ended July 31, 2024 and 2023, the Company capitalized $4,030 and $5,225, respectively, of costs related to the Company’s solutions. For the six months ended July 31, 2024 and 2023, the Company capitalized $8,418 and $10,371, respectively, of costs related to the Company’s solutions. During the three months ended July 31, 2024 and 2023, amortization expense related to capitalized internal-use software was $2,511 and $2,173, respectively. During the six months ended July 31, 2024 and 2023, amortization expense related to capitalized internal-use software was $4,790 and $4,316, respectively. (e) Intangible assets and goodwill The following presents the details of intangible assets as of July 31, 2024 and January 31, 2024: Useful Life (years) July 31, 2024 January 31, 2024 Acquired technology 5 to 7 $ 9,310 $ 9,310 Customer relationship 7 to 15 17,940 17,940 License 15 6,200 6,200 Trademarks 15 3,100 3,100 Total intangible assets, gross carrying value $ 36,550 $ 36,550 Less: accumulated amortization (6,666) (4,925) Net carrying value $ 29,884 $ 31,625 The weighted average remaining useful life for acquired technology in years was 5.5 and 6.0 as of July 31, 2024 and January 31, 2024, respectively. The remaining useful life for customer relationships in years was 12.0 and 12.4 as of July 31, 2024 and January 31, 2024, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years was 12.4 and 12.8 as of July 31, 2024 and January 31, 2024, respectively. The remaining useful life for the trademarks in years was 14.0 and 14.5 as of July 31, 2024 and January 31, 2024, respectively. Amortization expense associated with intangible assets for the three months ended July 31, 2024 and 2023, was $871 and $364, respectively. Amortization expense associated with intangible assets for the six months ended July 31, 2024 and 2023, was $1,741 and $707, respectively. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of July 31, 2024: July 31, 2024 2025 (Remaining six months) $ 1,742 Fiscal Years Ending January 31, 2026 3,450 2027 3,157 2028 3,157 2029 - thereafter 18,378 Total $ 29,884 There were no changes to the Company's goodwill balance during the six months ended July 31, 2024. The Company did not record any impairments of goodwill during the three and six months ended July 31, 2024 or 2023. (f) Accounts receivable Accounts receivable as of July 31, 2024 and January 31, 2024 are as follows: July 31, 2024 January 31, 2024 Billed $ 54,303 $ 62,880 Unbilled 8,336 3,375 Total accounts receivable, gross $ 62,639 $ 66,255 Less: accounts receivable allowances (1,365) (1,392) Total accounts receivable $ 61,274 $ 64,863 Activity in the Company's allowance for doubtful accounts was as follows for the six months ended July 31, 2024: July 31, 2024 Balance, January 31, 2024 $ 1,392 Bad debt expense 120 Write-offs and adjustments (147) Balance, July 31, 2024 $ 1,365 The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. The Company writes off accounts receivable and removes the associated allowance for doubtful accounts when the Company deems the receivables to be uncollectible. (g) Prepaid and other current assets Prepaid and other current assets as of July 31, 2024 and January 31, 2024 are as follows: July 31, 2024 January 31, 2024 Prepaid software and business systems $ 5,304 $ 4,922 Prepaid data center expenses 3,400 3,872 Prepaid insurance 266 1,257 Other prepaid expenses and other current assets 2,725 4,410 Total prepaid and other current assets $ 11,695 $ 14,461 (h) Cloud computing implementation costs The Company enters into cloud computing service contracts to support its sales and marketing, product development and administrative activities. The Company capitalizes certain implementation costs for cloud

Revenue and contract costs

Revenue and contract costs	6 Months Ended
	Jul. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue and contract costs	Revenue and contract costs The Company generates revenue primarily from providing integrated SaaS-based software and payment solutions for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Company’s solutions, payment processing fees based on patient payment volume, and fees from life sciences and payer clients for delivering qualified direct communications to patients who voluntarily opt in to receive this type of engagement using the Company’s solutions. The amount of subscription and related services revenue recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $2,324 and $2,603 for the three months ended July 31, 2024 and 2023, respectively. The amount of subscription and related services revenue recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $4,712 and $5,265 for the six months ended July 31, 2024 and 2023, respectively. Contract balances The following table represents a roll-forward of contract assets: Balance, January 31, 2024 $ 3,375 Amount transferred to receivables from beginning balance of contract assets (3,375) Contract asset additions, net of reclassification to receivables 8,336 Balance, July 31, 2024 $ 8,336 The following table represents a roll-forward of deferred revenue: Balance, January 31, 2024 $ 24,210 Revenue recognized that was included in deferred revenue at the beginning of the period (20,101) Other current period activity in deferred revenue 17,324 Balance, July 31, 2024 $ 21,433 Cost to obtain a contract The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be three The following table represents a roll forward of deferred contract acquisition costs: Balance, January 31, 2024 $ 1,754 Additions to deferred contract acquisition costs 213 Amortization of deferred contract acquisition costs (384) Balance, July 31, 2024 $ 1,583 Deferred contract acquisition costs, current (to be amortized in next 12 months) $ 841 Deferred contract acquisition costs, non-current 742 Total deferred contract acquisition costs $ 1,583

Finance leases and other debt

Finance leases and other debt	6 Months Ended
	Jul. 31, 2024
Debt Disclosure [Abstract]
Finance leases and other debt	Finance leases and other debt As of July 31, 2024 and January 31, 2024, the Company had the following outstanding finance lease liabilities and other debt: July 31, 2024 January 31, 2024 Finance leases $ 11,858 $ 8,309 Financing arrangements 2,539 3,124 Accrued interest and payments 61 23 Total finance lease liabilities and other debt $ 14,458 $ 11,456 Less: current portion of finance lease liabilities and other debt (7,161) (6,056) Long-term finance lease liabilities and other debt $ 7,297 $ 5,400 (a) Finance leases See Note 10 - Leases for more information regarding finance leases. (b) Financing agreements On June 8, 2023, the Company entered into a software licensing financing agreement (the "financing agreement") in order to finance its software and service licenses. As of July 31, 2024, there was $2,539 in outstanding principal and interest due under the financing agreement. The financing agreement requires the Company to pay $123 per month for 36 months beginning August 2023. The effective interest rate on the financing agreement is 10.5% per annum. (c) Amended and Restated Loan and Security Agreement with Silicon Valley Bank (“SVB”) On February 28, 2019 (the "Effective Date"), the Company entered into the Amended and Restated Loan and Security Agreement (the "First SVB Facility") that provided for a $20,000 term loan. On May 5, 2020 (the "Second SVB Effective Date"), the Company entered into the Second SVB Facility to modify the First SVB Facility. The Second SVB Facility provided for a revolving credit facility with an initial borrowing capacity of $50,000. On March 28, 2022 (the "Third SVB Effective Date"), the Company entered into a First Loan Modification Agreement to the Second SVB Facility (as amended, the "Third SVB Facility") to increase the borrowing capacity from $50,000 to $100,000 and to reduce the interest rate on the facility. Borrowings under the Third SVB Facility were payable on May 5, 2025. Borrowings under the Third SVB Facility bore interest, which was payable monthly, at a floating rate equal to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.5%. In addition to principal and interest due under the revolving credit facility, the Company was required to pay an annual commitment fee of approximately $250 per year and a quarterly fee of 0.15% per annum of the average unused revolving line under the facility. On December 4, 2023, the Company terminated the Third SVB Facility. (d) Capital One Credit Agreement On December 4, 2023, the Company entered into a Credit Agreement (the "Credit Agreement") for a new 5-year $50,000 senior secured asset-based revolving credit facility ("Capital One Credit Facility") maturing in December 2028, which includes a swingline sub-limit of at least $5,000 and a letter of credit sub-limit of at least $5,000. The Capital One Credit Facility was entered into with Capital One, N.A., acting as administrative agent and replaced our previous senior secured revolving credit facility with SVB. The Capital One Credit Facility gives the Company additional financial flexibility, through the facility’s five year term. The facility is available to the Company for working capital and general corporate purposes. The Capital One Credit Facility bears interest at a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) or a Base Rate as specified in the Credit Agreement. As of July 31, 2024, the interest rate on the Capital One Credit Facility was 8.4%. In addition to principal and interest due under the Capital One Credit Facility, the Company is required to pay an annual fee equal to 0.25% of the unused balance of the facility. Additionally, the Company incurred creditor and third party fees of $778 upon entering into the Capital One Credit Facility. The Company recorded the fees to deferred financing costs, included within other assets on its consolidated balance sheets, and will amortize the costs over the term of the Capital One Credit Facility. The obligations under the Capital One Credit Facility are secured by a first priority security interest in substantially all of the tangible and intangible assets at certain of the Company's U.S. subsidiaries, and by pledges of the equity of certain of the Company's U.S. subsidiaries, in each case subject to customary exclusions. The Capital One Credit Facility includes financial covenants including, but not limited to requiring the Company to maintain minimum Consolidated EBITDA, minimum Liquidity, a minimum Consolidated Fixed Charge Coverage Ratio a restriction on the amount of dividends and limiting the amount of cash and cash equivalents the Company holds outside Capital One, each as defined in the Credit Agreement. The Company was in compliance with all covenants related to the Credit Agreement as of July 31, 2024. Maturities of finance leases and other debt, in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt 2025 (Remaining six months) $ 4,006 $ 3,455 $ 551 Fiscal year ending January 31: 2026 6,456 5,126 1,330 2027 3,580 2,861 719 2028 416 416 — 2029 — — — Total maturities of finance leases and other debt $ 14,458 $ 11,858 $ 2,600 The following table presents the components of interest income, net: Three months ended Six months ended 2024 2023 2024 2023 Interest expense (1) $ (608) $ (420) $ (1,161) $ (713) Interest income 654 1,206 1,446 2,217 Interest income, net $ 46 $ 786 $ 285 $ 1,504 (1) Includes amortization of deferred financing costs and original issue discount.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jul. 31, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity (a) Common stock The Company closed an IPO on July 22, 2019 and filed an Amended and Restated Certificate of Incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share. In connection with the acquisition of Comsort, Inc. d/b/a MediFind ("MediFind") on June 30, 2023, the Company issued 150,786 shares of common stock, par value $0.01 per share, to the former owners of MediFind as partial consideration to acquire MediFind. On July 3, 2023, the Company filed a prospectus supplement to register the shares with the SEC. In connection with the acquisition of Access eForms, LLC ("Access") on August 11, 2023, the Company issued 1,096,436 shares of common stock, par value $0.01 per share, to the former members of Access as partial consideration to acquire Access. On August 14, 2023, the Company filed a prospectus supplement to register the shares with the SEC. (b) Treasury stock The Company's equity-based compensation plan allows for the grant of non-vested stock options, restricted stock units ("RSUs") and total shareholder return ("TSR") performance-based stock units ("PSUs") to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Until September 2023, under the provision of the plans, for RSU and PSU awards, unless otherwise elected, employee participants fulfilled their related income tax withholding obligation by having shares withheld at the time of vesting. The shares withheld were then transferred to the Company's treasury stock at cost. Beginning in September 2023, employee participants fulfilled their related tax withholding obligation by selling vested shares at the time of vesting in non-discretionary transactions pursuant to the Company’s mandatory sell-to-cover policy (sell-to-cover). The proceeds from the employee participants’ sales of vested shares is remitted to the Company to cover the tax withholding payments to tax authorities. No shares are transferred to the Company’s treasury stock in connection with tax withholdings funded by an employee participant’s sale of vested shares to cover taxes. (c) Accumulated other comprehensive loss Activity in accumulated other comprehensive loss was as follows for the six months ended July 31, 2024: Foreign Currency Translation Adjustment Accumulated Other Comprehensive Loss Balance as of January 31, 2024 $ — $ — Other comprehensive loss (2) (2) Balance as of July 31, 2024 $ (2) $ (2) There was no balance or activity in accumulated other comprehensive loss prior to January 31, 2024. The amounts set forth in the table above are presented net of tax. There were no amounts reclassified from accumulated other comprehensive loss into net loss during the six months ended July 31, 2024.

Equity-based compensation

Equity-based compensation	6 Months Ended
	Jul. 31, 2024
Share-Based Payment Arrangement [Abstract]
Equity-based compensation	Equity-based compensation (a) Equity award plans In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan (as amended, the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and automatically increases each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the six months ended July 31, 2024 were made pursuant to the 2019 plan, respectively. In June 2019, the Board of Directors also adopted the Company’s 2019 Employee Stock Purchase Plan (the "ESPP"), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP was limited to 855,873 shares. The Company's incentive bonuses allow eligible employees to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. In July 2023, the Board of Directors also adopted the Company’s 2023 Inducement Award Plan (the “Inducement Plan”). The Inducement Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") or its delegates to make equity-based incentive awards including stock options, RSUs and PSUs to employees of acquired companies to induce them to join the Company. The total shares of common stock initially reserved under the Inducement Plan was 500,000 shares. As of July 31, 2024, there are 6,269,312 shares available for future grant pursuant to the 2019 Plan after factoring in the automatic increase which occurs on February 1 of each fiscal year, as well as an additional 338,064 shares available for future grant pursuant to the ESPP. The ESPP has two six-month offering periods each calendar year beginning in January and July. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a 15% discount through payroll deductions. As of July 31, 2024, there were 16,210 outstanding restricted stock units and 483,790 shares available for future grant under the Inducement Plan. (b) Summary of stock-based compensation The following table sets forth stock-based compensation by type of award: Three months ended Six months ended 2024 2023 2024 2023 RSUs $ 10,960 $ 13,703 $ 22,283 $ 26,602 PSUs 3,483 2,751 6,287 4,395 Liability awards 2,024 2,278 4,721 4,803 ESPP 294 286 658 655 Stock options 2 7 2 45 Total stock-based compensation $ 16,763 $ 19,025 $ 33,951 $ 36,500 The following table sets forth the presentation of stock-based compensation in the Company's financial statements: Three months ended Six months ended 2024 2023 2024 2023 Stock-based compensation expense recorded to additional paid-in capital $ 14,739 $ 16,747 $ 29,230 $ 31,697 Stock-based compensation expense recorded to accrued expenses 2,024 2,278 4,721 4,803 Total stock-based compensation $ 16,763 $ 19,025 $ 33,951 $ 36,500 Less: stock-based compensation expense capitalized as internal-use software (315) (377) (663) (714) Stock-based compensation expense per consolidated statements of operations $ 16,448 $ 18,648 $ 33,288 $ 35,786 The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense. During the six months ended July 31, 2024, the Company reduced stock compensation expense by $1,203, for improbable-to-probable modifications of stock compensation awards. (c) Restricted stock units The Company has issued restricted stock units to employees and independent directors that vest based on a time-based condition. RSUs granted to employees vest over four years based on a variety of vesting schedules, including quarterly, annually, and 10/20/30/40 (10% after one year, 20% after two years, 30% after three years and 40% after four years). RSUs granted during fiscal 2024 generally vest annually, and RSUs granted during fiscal 2025 generally vest following a 10/20/30/40 vesting schedule. Additionally, at the beginning of each fiscal year, the Company provides eligible employees the option to settle their incentive bonus in immediately vested RSUs. During the six months ended July 31, 2024, the Company issued 285,279 immediately vested RSUs to settle full-year fiscal 2024 share-settled bonus awards. The RSUs granted to settle bonus awards are included in RSUs granted and vested in the table below. See section (g) Liability awards below for additional information regarding share-settled bonus awards. Restricted stock units Unvested, January 31, 2024 3,800,210 Granted in six months ended July 31, 2024 (1) 1,034,258 Vested (1,156,560) Forfeited and expired (170,430) Unvested, July 31, 2024 3,507,478 (1) Includes 16,210 awards granted pursuant to the 2023 Inducement Award Plan. As of July 31, 2024, there is $87,209 remaining of total unrecognized compensation cost related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 2.50 years. (d) Stock options Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis. Stock option activity for the six months ended July 31, 2024 is as follows: Number of Weighted- Weighted- Aggregate Outstanding — January 31, 2024 1,123,438 $ 6.89 Granted in six months ended July 31, 2024 — $ — Exercised (118,153) $ 4.79 Forfeited and expired (3,534) $ 20.67 Outstanding and expected to vest — July 31, 2024 1,001,751 $ 7.09 4.05 $ 17,902 Exercisable — July 31, 2024 1,001,751 $ 7.09 4.05 $ 17,902 The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the six months ended July 31, 2024 and 2023 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $2,165 and $4,214, respectively. As of July 31, 2024 and January 31, 2024, all compensation cost related to stock options issued to employees has been recorded and there is no unrecognized compensation cost remaining related to stock options issued to employees. (e) TSR performance-based restricted stock units (“PSUs”) The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Russell 3000 Index (the "Peer Group"). Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 220% of the number of PSUs originally granted. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 60th percentile, with the maximum number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%. The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model which projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period. Market-based PSU activity for the six months ended July 31, 2024 are as follows: Performance stock units Outstanding, January 31, 2024 1,040,219 Granted in six months ended July 31, 2024 — Vested — Forfeited and expired (14,248) Outstanding, July 31, 2024 1,025,971 As of July 31, 2024, unrecognized compensation cost for the PSUs was $22,802, to be recognized over a weighted average remaining vesting period of 2.2 years, subject to the participants' continued employment with the Company. (f) Employee stock purchase plan The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. T he ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986. During the three and six months ended July 31, 2024, the Company issued 89,220 shares of common stock under the ESPP. In connection with these issuances, the Company recorded increases of $1,608 to common stock and additional paid-in capital within stockholders' equity. As of July 31, 2024, unrecognized compensation cost related to the ESPP was $399, to be recognized over the next five months. (g) Liability awards At the beginning of each year, the Company provides eligible employees the option to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Share-settled bonus awards will be settled at a value equal to 115% of the cash bonuses. These share-settled bonus awards vest based on the achievement of the Company’s predefined performance targets. As share-settled bonus awards will be settled in a variable number of shares, the Company classifies share-settled bonus awards as liabilities within accrued expenses in the accompanying consolidated balance sheets until they are settled in shares and included in stockholders' equity. The Company’s share-settled bonus awards are settled semiannually. During the six months ended July 31, 2024, the Company settled $6,218 of share-settled bonus awards by issuing 285,279 immediately vested RSUs. See (c) Restricted Stock Units above for additional discussion regarding RSUs.

Fair value measurements

Fair value measurements	6 Months Ended
	Jul. 31, 2024
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements The following table presents information about the Company's assets and liabilities that are measured at fair value as of July 31, 2024 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of July 31, 2024 Money market mutual funds $ 68,165 $ — $ — $ 68,165 Total assets $ 68,165 $ — $ — $ 68,165 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2024 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2024 Money market mutual funds $ 58,942 $ — $ — $ 58,942 Total assets $ 58,942 $ — $ — $ 58,942 The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. As of July 31, 2024, the carrying value of the Company's debt and deferred consideration liabilities approximate fair value because the interest rates approximate market rates and the related maturities are relatively short-term. The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the six months ended July 31, 2024 and 2023.

Leases

Leases	6 Months Ended
	Jul. 31, 2024
Leases [Abstract]
Leases	Leases (a) Phreesia as Lessee The Company leases office premises and third-party data center space in the U.S. under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically three years and are secured by the underlying equipment. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of July 31, 2024, for operating leases, the weighted-average remaining lease term is 2.1 years and the weighted-average discount rate is 7.9%. As of July 31, 2024, for finance leases, the weighted-average remaining lease term is 2.1 years, and the weighted-average discount rate is 7.6%. The components of lease expense for the six months ended July 31, 2024 were as follows: July 31, 2024 Operating leases: Operating lease cost $ 439 Variable lease cost — Total operating lease cost $ 439 Finance leases: Amortization of right-of-use assets $ 3,378 Interest on lease liabilities 409 Total finance lease cost $ 3,787 Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations. The following represents a schedule of maturing lease commitments for operating and finance leases as of July 31, 2024: July 31, 2024 Operating Finance Maturity of lease liabilities 2025 (remaining six months) $ 568 $ 3,761 Fiscal year ending January 31, 2026 1,053 5,580 2027 583 3,114 2028 34 453 Thereafter — — Total future minimum lease payments $ 2,238 $ 12,908 Less: interest (174) (1,050) Present value of lease liabilities $ 2,064 $ 11,858 As of July 31, 2024, the Company has signed a finance lease for computer equipment which does not commence until October 2024. Total undiscounted payments through the fiscal year ended January 31, 2028 related to the lease are $7,408 and are excluded from the table above but are included in the Company's other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the six months ended July 31, 2024 was as follows: July 31, 2024 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 498 Operating cash used for finance leases 409 Financing cash used for finance leases 3,275 Right-of-use assets obtained in exchange for lease liabilities: Operating $ 1,958 Finance 6,862 Total $ 8,820 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the three and six months ended July 31, 2024, the Company recognized $2,324 and $4,712, respectively, in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases office premises and third-party data center space in the U.S. under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically three years and are secured by the underlying equipment. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of July 31, 2024, for operating leases, the weighted-average remaining lease term is 2.1 years and the weighted-average discount rate is 7.9%. As of July 31, 2024, for finance leases, the weighted-average remaining lease term is 2.1 years, and the weighted-average discount rate is 7.6%. The components of lease expense for the six months ended July 31, 2024 were as follows: July 31, 2024 Operating leases: Operating lease cost $ 439 Variable lease cost — Total operating lease cost $ 439 Finance leases: Amortization of right-of-use assets $ 3,378 Interest on lease liabilities 409 Total finance lease cost $ 3,787 Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations. The following represents a schedule of maturing lease commitments for operating and finance leases as of July 31, 2024: July 31, 2024 Operating Finance Maturity of lease liabilities 2025 (remaining six months) $ 568 $ 3,761 Fiscal year ending January 31, 2026 1,053 5,580 2027 583 3,114 2028 34 453 Thereafter — — Total future minimum lease payments $ 2,238 $ 12,908 Less: interest (174) (1,050) Present value of lease liabilities $ 2,064 $ 11,858 As of July 31, 2024, the Company has signed a finance lease for computer equipment which does not commence until October 2024. Total undiscounted payments through the fiscal year ended January 31, 2028 related to the lease are $7,408 and are excluded from the table above but are included in the Company's other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the six months ended July 31, 2024 was as follows: July 31, 2024 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 498 Operating cash used for finance leases 409 Financing cash used for finance leases 3,275 Right-of-use assets obtained in exchange for lease liabilities: Operating $ 1,958 Finance 6,862 Total $ 8,820 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the three and six months ended July 31, 2024, the Company recognized $2,324 and $4,712, respectively, in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases office premises and third-party data center space in the U.S. under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically three years and are secured by the underlying equipment. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of July 31, 2024, for operating leases, the weighted-average remaining lease term is 2.1 years and the weighted-average discount rate is 7.9%. As of July 31, 2024, for finance leases, the weighted-average remaining lease term is 2.1 years, and the weighted-average discount rate is 7.6%. The components of lease expense for the six months ended July 31, 2024 were as follows: July 31, 2024 Operating leases: Operating lease cost $ 439 Variable lease cost — Total operating lease cost $ 439 Finance leases: Amortization of right-of-use assets $ 3,378 Interest on lease liabilities 409 Total finance lease cost $ 3,787 Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations. The following represents a schedule of maturing lease commitments for operating and finance leases as of July 31, 2024: July 31, 2024 Operating Finance Maturity of lease liabilities 2025 (remaining six months) $ 568 $ 3,761 Fiscal year ending January 31, 2026 1,053 5,580 2027 583 3,114 2028 34 453 Thereafter — — Total future minimum lease payments $ 2,238 $ 12,908 Less: interest (174) (1,050) Present value of lease liabilities $ 2,064 $ 11,858 As of July 31, 2024, the Company has signed a finance lease for computer equipment which does not commence until October 2024. Total undiscounted payments through the fiscal year ended January 31, 2028 related to the lease are $7,408 and are excluded from the table above but are included in the Company's other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the six months ended July 31, 2024 was as follows: July 31, 2024 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 498 Operating cash used for finance leases 409 Financing cash used for finance leases 3,275 Right-of-use assets obtained in exchange for lease liabilities: Operating $ 1,958 Finance 6,862 Total $ 8,820 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the three and six months ended July 31, 2024, the Company recognized $2,324 and $4,712, respectively, in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jul. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies (a) Indemnifications The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued a ny liabilities related to such obligations in its consolidated financial statements. In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceedi n g to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions. (b) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows. (c) Other contractual commitments Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure as well commitments related to our acquisitions. As of July 31, 2024, the Company has signed a finance lease for computer equipment which is not expected to commence until the fiscal quarter ended October 31, 2024. Total undiscounted payments through the fiscal year ended January 31, 2028 related to the lease are $7,408 and are included in our other contractual purchase commitments. As of July 31, 2024, the Company has signed two non-cancelable purchase commitments to support its technology infrastructure which are not expected to commence until the fiscal quarter ended October 31, 2024. Total undiscounted payments for the agreements through the fiscal year ended January 31, 2028 related to the agreements are $9,594 and are included in our other contractual purchase commitments. During fiscal 2024, the Company signed a finance lease which commenced during the six months ended July 31, 2024. Total undiscounted payments through the fiscal year ended January 31, 2028 related to the lease of $7,413 were included in other contractual commitments as of January 31, 2024 and were added at present value to finance lease liabilities during the six months ended July 31, 2024.

Income taxes

Income taxes	6 Months Ended
	Jul. 31, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes For the three and six months ended July 31, 2024, the Company recorded a tax provision of $750 and $1,260, respectively, compared to a tax provision of $648 and $954, respectively, for the corresponding periods in the prior year. The Company's provision for income taxes was 3.5% and 1.3% of loss before income taxes for the six months ended July 31, 2024 and 2023, respectively. The Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against its U.S. deferred tax assets, and due to foreign income tax expense related to its Canadian branch and its subsidiary in India.

Net loss per share attributable

Net loss per share attributable to common stockholders	6 Months Ended
	Jul. 31, 2024
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	Net loss per share attributable to common stockholders (a) Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three months ended Six months ended 2024 2023 2024 2023 Numerator: Net loss $ (18,012) $ (36,767) $ (37,734) $ (74,298) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 57,502,959 53,794,060 57,089,232 53,574,584 Net loss per share attributable to common stockholders $ (0.31) $ (0.68) $ (0.66) $ (1.39) (b) Potential dilutive securities The Company’s potential dilutive securities, which include stock options, restricted stock units, performance stock awards and grants under the Company's ESPP, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of July 31, 2024 2023 Stock options to purchase common stock, restricted stock and performance stock awards 6,795,068 7,167,904 Employee stock purchase plan 82,784 72,501 Total 6,877,852 7,240,405

Related party transactions

Related party transactions	6 Months Ended
	Jul. 31, 2024
Related Party Transactions [Abstract]
Related party transactions	Related party transactions For the three months ended July 31, 2024 and 2023, the Company recognized revenue totaling $343 and $261, respectively, for advertisements placed by a pharmaceutical company. For the six months ended July 31, 2024 and 2023, the Company recognized revenue totaling $671 and $549, respectively, for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of July 31, 2024 and January 31, 2024, accounts receivable from the pharmaceutical company totaled approximately $116 and $416, respectively. For the six months ended July 31, 2023, the Company recognized general and administrative expenses totaling $118 for software agreements with a software company. One of the Company's independent members of its board of directors served as the chief executive officer and on the board of directors for this software company until May 2023. This Company is no longer considered a related party subsequent to May 2023. The expense amounts presented above include amounts incurred while the entity was a related party. One of the Company's independent members of its board of directors has served as the chief financial officer of a software company since April 2022. The Company recognized de minimis expenses during both the three and six months ended July 31, 2024 and 2023 under software agreements with this software company.

Acquisitions

Acquisitions	6 Months Ended
	Jul. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	Acquisitions Acquisition of MediFind On June 30, 2023, the Company entered into an agreement to acquire 100% of the outstanding equity of MediFind for aggregate consideration payable of $8,871 (the "MediFind Acquisition"). A portion of the consideration was paid in cash at closing (subject to a customary working capital adjustment) with the remainder of the consideration settled through the issuance of 150,786 shares of the Company's common stock to certain stockholders of MediFind. MediFind is a consumer-facing healthcare product that helps patients - especially those with serious, chronic and rare diseases - find better care faster. The MediFind Acquisition was accounted for as a business combination. The Company acquired MediFind to reinforce its commitment to patient-centered care and expand its offerings to consumers. The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid to sellers $ 4,104 Equity consideration paid to sellers 4,676 Liabilities incurred to sellers 91 Total fair value of acquisition consideration $ 8,871 Cash consideration $ 4,104 Less: Cash acquired (231) Cash paid for MediFind Acquisition net of cash acquired per statement of cash flows $ 3,873 The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by ASC 805 - Business Combinations. The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition: Cash $ 231 Accounts receivable 149 Other current assets 722 Identified intangible assets acquired 2,300 Goodwill 6,821 Total assets acquired 10,223 Accounts payable (121) Accrued liabilities (816) Deferred revenue (292) Deferred income tax liabilities (123) Total purchase price $ 8,871 The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value Technology 7 $ 1,200 Trademark 15 700 Customer relationships 10 400 Total identifiable intangible assets acquired $ 2,300 The weighted average amortization period for acquired intangible assets as of the date of the acquisition is 10 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of MediFind. The fair value of the acquired technology and trademark assets of MediFind were estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi-period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each asset. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not expected to be deductible for income tax purposes. The goodwill recognized in the MediFind Acquisition is primarily attributable to expected synergies of the combined businesses driven by integrating the technology into our solutions and engaging with patients and providers, as well as the acquisition of an assembled workforce. The goodwill is not expected to be deductible for tax purposes. During the six months ended July 31, 2023, the Company incurred $699 of acquisition related costs for the MediFind Acquisition. These costs are primarily included within general and administrative expenses in our consolidated statements of operations.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jul. 31, 2024	Apr. 30, 2024	Jul. 31, 2023	Apr. 30, 2023	Jul. 31, 2024	Jul. 31, 2023
Pay vs Performance Disclosure
Net loss	$ (18,012)	$ (19,722)	$ (36,767)	$ (37,531)	$ (37,734)	$ (74,298)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jul. 31, 2024 shares	Jul. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Michael Weintraub [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On June 6, 2024, Michael Weintraub, the chairperson of the Company’s Board of Directors, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Weintraub’s Rule 10b5-1 Trading Plan provides for the potential exercise of vested stock options and the associated sale of up to 55,152 shares of the Company’s common stock. The plan expires on September 30, 2025, or upon the earlier completion of all authorized transactions under the plan.
Name	Michael Weintraub
Title	chairperson of the Company’s Board of Directors
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 6, 2024
Expiration Date	September 30, 2025
Arrangement Duration	481 days
Aggregate Available	55,152	55,152
Yvonne Hui [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On July 16, 2024, Yvonne Hui, the Principal Accounting Officer of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Ms. Hui’s Rule 10b5-1 Trading Plan provides for the sale of up to 8,417 shares of common stock, plus an additional number of shares that Ms. Hui could receive upon the vesting of certain equity awards that may be granted pursuant to her first half fiscal 2025 bonus and certain equity awards that she may receive due to her participation in the Company’s Employee Stock Purchase Plan (“ESPP”), net of any shares sold in non-discretionary transactions pursuant to the Company’s mandatory sell-to-cover policy to cover Ms. Hui’s tax withholding obligations in connection with the vesting and settlement of restricted stock unit awards. The number of shares to be granted pursuant to Ms. Hui’s first half fiscal year 2025 bonus and to be purchased by Ms. Hui through the Company’s ESPP, and the number of shares to be sold by her to cover taxes, and thus the exact number of shares to be sold pursuant to Ms. Hui’s Rule 105b-1 Trading Plan, can only be determined upon the occurrence of future events. Ms. Hui’s Rule 10b5-1 Trading Plan expires on July 31, 2025, or upon the earlier completion of all authorized transactions under the plan.
Name	Yvonne Hui,
Title	Principal Accounting Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	July 16, 2024
Expiration Date	July 31, 2025
Arrangement Duration	380 days
Aggregate Available	8,417	8,417
David Linetsky, SVP [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On July 18, 2024, David Linetsky, SVP, Life Sciences of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Linetsky’s Rule 10b5-1 Trading Plan provides for the potential exercise of vested stock options and the associated sale of up to 49,299 shares of the Company’s common stock, plus an additional number of shares that Mr. Linetsky could receive upon the vesting of certain equity awards that may be granted pursuant to his first half fiscal 2025 bonus, net of any shares sold in non-discretionary transactions pursuant to the Company’s mandatory sell-to-cover policy to cover Mr. Linetsky’s tax withholding obligations in connection with the vesting and settlement of restricted stock unit awards. The number of shares to be granted pursuant to Mr. Linetsky’s first half fiscal year 2025 bonus, and the number of shares to be sold by him to cover taxes, and thus the exact number of shares to be sold pursuant to Mr. Linetsky’s Rule 105b-1 Trading Plan, can only be determined upon the occurrence of future events. Mr. Linetsky’s Rule 10b5-1 Trading Plan expires on March 31, 2025, or upon the earlier completion of all authorized transactions under the plan.
Name	David Linetsky
Title	SVP, Life Sciences
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	July 18, 2024
Expiration Date	March 31, 2025
Arrangement Duration	256 days
Aggregate Available	49,299	49,299
Evan Roberts December 2023 Plan [Member] | Evan Roberts [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On July 17, 2024, Evan Roberts, the Company’s Chief Operating Officer, terminated a Rule 10b5-1 Trading Plan he had previously adopted with respect to the sale of the Company’s common stock that is intended to satisfy the
Name	Evan Roberts
Title	Chief Operating Officer
Rule 10b5-1 Arrangement Terminated	true
Termination Date	July 17, 2024
Aggregate Available	84,712	84,712
Evan Roberts July 2024 Plan [Member] | Evan Roberts [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		In addition, on July 17, 2024, Mr. Roberts, adopted a new 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Roberts’ Rule 10b5-1 Trading Plan provides for the potential exercise of vested stock options and the associated sale of up to 58,750 shares of the Company’s common stock. The plan expires on July 18, 2025, or upon the earlier completion of all authorized transactions under the plan.
Name	Mr. Roberts
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	July 17, 2024
Expiration Date	July 18, 2025
Arrangement Duration	366 days
Aggregate Available	58,750	58,750

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jul. 31, 2024
Accounting Policies [Abstract]
Consolidated financial statements	Consolidated financial statementsThe accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding quarterly financial reporting and include the accounts of Phreesia, Inc., its branch operation in Canada and its consolidated subsidiaries (or collectively, the "Company").
Fiscal year	Fiscal yearThe Company’s fiscal year ends on January 31. References to fiscal 2025 and 2024 refer to the fiscal years ending on January 31, 2025 and January 31, 2024, respectively.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other market-specific factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results could differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets.
Concentrations of credit risk	Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two
Risks and uncertainties	Risks and uncertaintiesThe Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. The Company supplements its workforce with contractors and consultants, including a substantial number of contractors and consultants in international locations. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments.
Foreign currency	Foreign currency The functional currency of the Company’s subsidiaries and branch in the U.S. and Canada is the US Dollar. The functional currency of the Company’s subsidiary in India is the Indian Rupee. For subsidiaries with functional currencies other than the US Dollar, the Company translates the functional currency financial statements into US Dollars using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign
New accounting pronouncements	New accounting pronouncements Impact of recently adopted accounting pronouncements During the three and six months ended July 31, 2024, the Company did not adopt any accounting pronouncements that materially impacted the Company's financial statements. Recent accounting pronouncements not yet adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting. The new standard requires enhanced disclosures about significant segment expenses and other segment items and requires companies to disclose all annual disclosures about segments in interim periods. The new standard also permits companies to disclose more than one measure of segment profit or loss, requires disclosure of the title and position of the Chief Operating Decision Maker, and requires companies with a single reportable segment to provide all disclosures required by Topic 280 – Segment Reporting. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Companies are required to apply ASU 2023-07 retrospectively to all periods presented. The Company is currently evaluating the impact that ASU 2023-07 will have on its financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024; early adoption is permitted for annual statements. The Company is currently evaluating the impact that ASU 2023-09 will have on its financial statements and related disclosures. There are no other recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	6 Months Ended
	Jul. 31, 2024
Composition of Certain Financial Statements [Abstract]
Schedule of Accrued Expenses	Accrued expenses as of July 31, 2024 and January 31, 2024 are as follows: July 31, 2024 January 31, 2024 Payroll-related expenses and taxes $ 11,664 $ 8,981 Stock-based compensation liability 4,393 5,890 Payment processing fees liability 5,517 6,008 Acquisition-related liabilities 997 1,888 Income and other tax liabilities 2,005 3,042 Information technology 4,971 5,927 Other 3,121 5,394 Total $ 32,668 $ 37,130
Schedule of Property and Equipment	Property and equipment as of July 31, 2024 and January 31, 2024 are as follows: Useful Life (years) July 31, 2024 January 31, 2024 PhreesiaPads and Arrivals Kiosks 3 $ 20,858 $ 18,610 Computer equipment 3 70,250 62,888 Computer software 3 to 5 13,567 11,687 Hardware development 3 575 576 Total property and equipment $ 105,250 $ 93,761 Less: accumulated depreciation (84,295) (76,859) Property and equipment — net $ 20,955 $ 16,902
Schedule of Intangible Assets	The following presents the details of intangible assets as of July 31, 2024 and January 31, 2024: Useful Life (years) July 31, 2024 January 31, 2024 Acquired technology 5 to 7 $ 9,310 $ 9,310 Customer relationship 7 to 15 17,940 17,940 License 15 6,200 6,200 Trademarks 15 3,100 3,100 Total intangible assets, gross carrying value $ 36,550 $ 36,550 Less: accumulated amortization (6,666) (4,925) Net carrying value $ 29,884 $ 31,625
Schedule of Estimated Amortization Expense for Intangible Assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of July 31, 2024: July 31, 2024 2025 (Remaining six months) $ 1,742 Fiscal Years Ending January 31, 2026 3,450 2027 3,157 2028 3,157 2029 - thereafter 18,378 Total $ 29,884
Schedule of Accounts Receivable	Accounts receivable as of July 31, 2024 and January 31, 2024 are as follows: July 31, 2024 January 31, 2024 Billed $ 54,303 $ 62,880 Unbilled 8,336 3,375 Total accounts receivable, gross $ 62,639 $ 66,255 Less: accounts receivable allowances (1,365) (1,392) Total accounts receivable $ 61,274 $ 64,863
Schedule of Allowance for Doubtful Accounts	Activity in the Company's allowance for doubtful accounts was as follows for the six months ended July 31, 2024: July 31, 2024 Balance, January 31, 2024 $ 1,392 Bad debt expense 120 Write-offs and adjustments (147) Balance, July 31, 2024 $ 1,365
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets as of July 31, 2024 and January 31, 2024 are as follows: July 31, 2024 January 31, 2024 Prepaid software and business systems $ 5,304 $ 4,922 Prepaid data center expenses 3,400 3,872 Prepaid insurance 266 1,257 Other prepaid expenses and other current assets 2,725 4,410 Total prepaid and other current assets $ 11,695 $ 14,461

Revenue and contract costs (Tab

Revenue and contract costs (Tables)	6 Months Ended
	Jul. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Rollforward of Contract Assets and Contract Liabilities	The following table represents a roll-forward of contract assets: Balance, January 31, 2024 $ 3,375 Amount transferred to receivables from beginning balance of contract assets (3,375) Contract asset additions, net of reclassification to receivables 8,336 Balance, July 31, 2024 $ 8,336 The following table represents a roll-forward of deferred revenue: Balance, January 31, 2024 $ 24,210 Revenue recognized that was included in deferred revenue at the beginning of the period (20,101) Other current period activity in deferred revenue 17,324 Balance, July 31, 2024 $ 21,433
Schedule of Deferred Contract Acquisition Costs	The following table represents a roll forward of deferred contract acquisition costs: Balance, January 31, 2024 $ 1,754 Additions to deferred contract acquisition costs 213 Amortization of deferred contract acquisition costs (384) Balance, July 31, 2024 $ 1,583 Deferred contract acquisition costs, current (to be amortized in next 12 months) $ 841 Deferred contract acquisition costs, non-current 742 Total deferred contract acquisition costs $ 1,583

Finance leases and other debt (

Finance leases and other debt (Tables)	6 Months Ended
	Jul. 31, 2024
Debt Disclosure [Abstract]
Schedule of Outstanding Finance Lease Liabilities and Other Debt	As of July 31, 2024 and January 31, 2024, the Company had the following outstanding finance lease liabilities and other debt: July 31, 2024 January 31, 2024 Finance leases $ 11,858 $ 8,309 Financing arrangements 2,539 3,124 Accrued interest and payments 61 23 Total finance lease liabilities and other debt $ 14,458 $ 11,456 Less: current portion of finance lease liabilities and other debt (7,161) (6,056) Long-term finance lease liabilities and other debt $ 7,297 $ 5,400
Schedule of Maturities of Finance Leases and Other Debt	Maturities of finance leases and other debt, in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt 2025 (Remaining six months) $ 4,006 $ 3,455 $ 551 Fiscal year ending January 31: 2026 6,456 5,126 1,330 2027 3,580 2,861 719 2028 416 416 — 2029 — — — Total maturities of finance leases and other debt $ 14,458 $ 11,858 $ 2,600
Schedule of Components of Interest Income (Expense), Net	The following table presents the components of interest income, net: Three months ended Six months ended 2024 2023 2024 2023 Interest expense (1) $ (608) $ (420) $ (1,161) $ (713) Interest income 654 1,206 1,446 2,217 Interest income, net $ 46 $ 786 $ 285 $ 1,504 (1) Includes amortization of deferred financing costs and original issue discount.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jul. 31, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	Activity in accumulated other comprehensive loss was as follows for the six months ended July 31, 2024: Foreign Currency Translation Adjustment Accumulated Other Comprehensive Loss Balance as of January 31, 2024 $ — $ — Other comprehensive loss (2) (2) Balance as of July 31, 2024 $ (2) $ (2)

Equity-based compensation (Tabl

Equity-based compensation (Tables)	6 Months Ended
	Jul. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock - Based Compensation by Type of Award	The following table sets forth stock-based compensation by type of award: Three months ended Six months ended 2024 2023 2024 2023 RSUs $ 10,960 $ 13,703 $ 22,283 $ 26,602 PSUs 3,483 2,751 6,287 4,395 Liability awards 2,024 2,278 4,721 4,803 ESPP 294 286 658 655 Stock options 2 7 2 45 Total stock-based compensation $ 16,763 $ 19,025 $ 33,951 $ 36,500
Schedule of Stock-Based Compensation in Financial Statements	The following table sets forth the presentation of stock-based compensation in the Company's financial statements: Three months ended Six months ended 2024 2023 2024 2023 Stock-based compensation expense recorded to additional paid-in capital $ 14,739 $ 16,747 $ 29,230 $ 31,697 Stock-based compensation expense recorded to accrued expenses 2,024 2,278 4,721 4,803 Total stock-based compensation $ 16,763 $ 19,025 $ 33,951 $ 36,500 Less: stock-based compensation expense capitalized as internal-use software (315) (377) (663) (714) Stock-based compensation expense per consolidated statements of operations $ 16,448 $ 18,648 $ 33,288 $ 35,786
Schedule of Restricted Stock Unit Activity	Restricted stock units Unvested, January 31, 2024 3,800,210 Granted in six months ended July 31, 2024 (1) 1,034,258 Vested (1,156,560) Forfeited and expired (170,430) Unvested, July 31, 2024 3,507,478 (1) Includes 16,210 awards granted pursuant to the 2023 Inducement Award Plan.
Schedule of Stock Option Activity	Stock option activity for the six months ended July 31, 2024 is as follows: Number of Weighted- Weighted- Aggregate Outstanding — January 31, 2024 1,123,438 $ 6.89 Granted in six months ended July 31, 2024 — $ — Exercised (118,153) $ 4.79 Forfeited and expired (3,534) $ 20.67 Outstanding and expected to vest — July 31, 2024 1,001,751 $ 7.09 4.05 $ 17,902 Exercisable — July 31, 2024 1,001,751 $ 7.09 4.05 $ 17,902
Schedule of Market-Based Performance Stock Unit Activity	Market-based PSU activity for the six months ended July 31, 2024 are as follows: Performance stock units Outstanding, January 31, 2024 1,040,219 Granted in six months ended July 31, 2024 — Vested — Forfeited and expired (14,248) Outstanding, July 31, 2024 1,025,971

Fair value measurements (Tables

Fair value measurements (Tables)	6 Months Ended
	Jul. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents information about the Company's assets and liabilities that are measured at fair value as of July 31, 2024 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of July 31, 2024 Money market mutual funds $ 68,165 $ — $ — $ 68,165 Total assets $ 68,165 $ — $ — $ 68,165 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2024 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2024 Money market mutual funds $ 58,942 $ — $ — $ 58,942 Total assets $ 58,942 $ — $ — $ 58,942

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jul. 31, 2024
Leases [Abstract]
Schedule of Lease Expense and Other Supplemental Cash Flow Information	The components of lease expense for the six months ended July 31, 2024 were as follows: July 31, 2024 Operating leases: Operating lease cost $ 439 Variable lease cost — Total operating lease cost $ 439 Finance leases: Amortization of right-of-use assets $ 3,378 Interest on lease liabilities 409 Total finance lease cost $ 3,787 Other supplemental cash flow information for the six months ended July 31, 2024 was as follows: July 31, 2024 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 498 Operating cash used for finance leases 409 Financing cash used for finance leases 3,275 Right-of-use assets obtained in exchange for lease liabilities: Operating $ 1,958 Finance 6,862 Total $ 8,820
Schedule of Maturities of Operating Leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of July 31, 2024: July 31, 2024 Operating Finance Maturity of lease liabilities 2025 (remaining six months) $ 568 $ 3,761 Fiscal year ending January 31, 2026 1,053 5,580 2027 583 3,114 2028 34 453 Thereafter — — Total future minimum lease payments $ 2,238 $ 12,908 Less: interest (174) (1,050) Present value of lease liabilities $ 2,064 $ 11,858
Schedule of Maturities of Finance Leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of July 31, 2024: July 31, 2024 Operating Finance Maturity of lease liabilities 2025 (remaining six months) $ 568 $ 3,761 Fiscal year ending January 31, 2026 1,053 5,580 2027 583 3,114 2028 34 453 Thereafter — — Total future minimum lease payments $ 2,238 $ 12,908 Less: interest (174) (1,050) Present value of lease liabilities $ 2,064 $ 11,858

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	6 Months Ended
	Jul. 31, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three months ended Six months ended 2024 2023 2024 2023 Numerator: Net loss $ (18,012) $ (36,767) $ (37,734) $ (74,298) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 57,502,959 53,794,060 57,089,232 53,574,584 Net loss per share attributable to common stockholders $ (0.31) $ (0.68) $ (0.66) $ (1.39)
Schedule of Shares Excluded from Computation of Diluted Net Loss Per Share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of July 31, 2024 2023 Stock options to purchase common stock, restricted stock and performance stock awards 6,795,068 7,167,904 Employee stock purchase plan 82,784 72,501 Total 6,877,852 7,240,405

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jul. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Purchase Price Considerations at Acquisition Date	The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid to sellers $ 4,104 Equity consideration paid to sellers 4,676 Liabilities incurred to sellers 91 Total fair value of acquisition consideration $ 8,871 Cash consideration $ 4,104 Less: Cash acquired (231) Cash paid for MediFind Acquisition net of cash acquired per statement of cash flows $ 3,873
Schedule of Allocation of Purchase Price of Assets Acquired and Liabilities Assumed	The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition: Cash $ 231 Accounts receivable 149 Other current assets 722 Identified intangible assets acquired 2,300 Goodwill 6,821 Total assets acquired 10,223 Accounts payable (121) Accrued liabilities (816) Deferred revenue (292) Deferred income tax liabilities (123) Total purchase price $ 8,871
Schedule of Intangible Assets Acquired	The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value Technology 7 $ 1,200 Trademark 15 700 Customer relationships 10 400 Total identifiable intangible assets acquired $ 2,300

Background and liquidity (Detai

Background and liquidity (Details)	6 Months Ended
	Jul. 31, 2024
Third SVB Facility
Debt Instrument [Line Items]
Number of months with sufficient funds to operate (in months)	12 months

Summary of significant accoun_3

Summary of significant accounting policies (Details)	6 Months Ended
	Jul. 31, 2024 processor
Concentration Risk [Line Items]
Number of third-party payment processors	1
Minimum
Concentration Risk [Line Items]
Customer payment period (in days)	30 days
Settlement period (in days)	1 day
Maximum
Concentration Risk [Line Items]
Customer payment period (in days)	60 days
Settlement period (in days)	2 days

Composition of certain financ_3

Composition of certain financial statement captions - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Composition of Certain Financial Statements [Abstract]
Payroll-related expenses and taxes	$ 11,664	$ 8,981
Stock-based compensation liability	4,393	5,890
Payment processing fees liability	5,517	6,008
Acquisition-related liabilities	997	1,888
Income and other tax liabilities	2,005	3,042
Information technology	4,971	5,927
Other	3,121	5,394
Total	$ 32,668	$ 37,130

Composition of certain financ_4

Composition of certain financial statement captions - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Jan. 31, 2024
Composition of Certain Financial Statements [Line Items]
Other current liabilities	$ 7,515,000		$ 7,515,000		$ 5,875,000
Other long-term liabilities	76,000		76,000		2,857,000
Depreciation	3,921,000	$ 4,244,000	7,445,000	$ 8,748,000
Capitalized cost of computer software	4,030,000	5,225,000	8,418,000	10,371,000
Capitalized computed software amortization	2,511,000	2,173,000	4,790,000	4,316,000
Amortization of intangible assets	871,000	364,000	1,741,000	707,000
Changes in goodwill balance			0
Goodwill, impairment loss	0	$ 0	0	$ 0
Capitalized implementation costs	1,532,000		1,532,000		1,532,000
Capitalized implementation costs, accumulated amortization	$ 1,225,000		$ 1,225,000		$ 1,021,000
Acquired technology
Composition of Certain Financial Statements [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	5 years 6 months		5 years 6 months		6 years
Customer relationship
Composition of Certain Financial Statements [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	12 years		12 years		12 years 4 months 24 days
License
Composition of Certain Financial Statements [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	12 years 4 months 24 days		12 years 4 months 24 days		12 years 9 months 18 days
Trademarks
Composition of Certain Financial Statements [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	14 years		14 years		14 years 6 months
Computer Equipment
Composition of Certain Financial Statements [Line Items]
Assets acquired under finance leases	$ 42,112,000		$ 42,112,000		$ 35,250,000
Assets under finance lease, accumulated amortization	$ 30,777,000		$ 30,777,000		$ 27,399,000

Composition of certain financ_5

Composition of certain financial statement captions - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 105,250	$ 93,761
Less: accumulated depreciation	(84,295)	(76,859)
Property and equipment — net	$ 20,955	16,902
PhreesiaPads and Arrivals Kiosks
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 20,858	18,610
Computer equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 70,250	62,888
Computer software
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 13,567	11,687
Computer software | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Computer software | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Hardware development
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 575	$ 576

Composition of certain financ_6

Composition of certain financial statement captions - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 36,550	$ 36,550
Less: accumulated amortization	(6,666)	(4,925)
Net carrying value	29,884	31,625
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 9,310	9,310
Acquired technology | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	5 years
Acquired technology | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	7 years
Customer relationship
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 17,940	17,940
Customer relationship | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	7 years
Customer relationship | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
License
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
Total intangible assets, gross carrying value	$ 6,200	6,200
Trademarks
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
Total intangible assets, gross carrying value	$ 3,100	$ 3,100

Composition of certain financ_7

Composition of certain financial statement captions - Schedule of Estimated Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Composition of Certain Financial Statements [Abstract]
2025 (Remaining six months)	$ 1,742
2026	3,450
2027	3,157
2028	3,157
2029 - thereafter	18,378
Net carrying value	$ 29,884	$ 31,625

Composition of certain financ_8

Composition of certain financial statement captions - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Composition of Certain Financial Statements [Abstract]
Billed	$ 54,303	$ 62,880
Unbilled	8,336	3,375
Total accounts receivable, gross	62,639	66,255
Less: accounts receivable allowances	(1,365)	(1,392)
Total accounts receivable	$ 61,274	$ 64,863

Composition of certain financ_9

Composition of certain financial statement captions - Schedule of Allowance for Doubtful Accounts (Details) $ in Thousands	6 Months Ended
	Jul. 31, 2024 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance, January 31, 2024	$ 1,392
Bad debt expense	120
Write-offs and adjustments	(147)
Balance, July 31, 2024	$ 1,365

Composition of certain finan_10

Composition of certain financial statement captions - Schedule of Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Composition of Certain Financial Statements [Abstract]
Prepaid software and business systems	$ 5,304	$ 4,922
Prepaid data center expenses	3,400	3,872
Prepaid insurance	266	1,257
Other prepaid expenses and other current assets	2,725	4,410
Total prepaid and other current assets	$ 11,695	$ 14,461

Revenue and contract costs - Na

Revenue and contract costs - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Revenue from External Customer [Line Items]
Capitalized contract cost, amortization	$ 192,000	$ 280,000	$ 384,000	$ 620,000
Capitalized contract cost, impairment loss	$ 0	0
Minimum
Revenue from External Customer [Line Items]
Capitalized contract cost, amortization period (in years)	3 years		3 years
Maximum
Revenue from External Customer [Line Items]
Capitalized contract cost, amortization period (in years)	5 years		5 years
Subscription and Related Services
Revenue from External Customer [Line Items]
Lease income	$ 2,324,000	$ 2,603,000	$ 4,712,000	$ 5,265,000

Revenue and contract costs - Sc

Revenue and contract costs - Schedule of Rollforward of Contract Assets and Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Jul. 31, 2024 USD ($)
Contract with Customer Asset [Roll Forward]
Beginning balance	$ 3,375
Amount transferred to receivables from beginning balance of contract assets	(3,375)
Contract asset additions, net of reclassification to receivables	8,336
Ending balance	8,336
Contract with Customer Liability [Roll Forward]
Beginning balance	24,210
Revenue recognized that was included in deferred revenue at the beginning of the period	(20,101)
Other current period activity in deferred revenue	17,324
Ending balance	$ 21,433

Revenue and contract costs - _2

Revenue and contract costs - Schedule of Deferred Contract Acquisition Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Jan. 31, 2024
Capitalized Contract Cost [Roll Forward]
Beginning balance			$ 1,754
Additions to deferred contract acquisition costs			213
Amortization of deferred contract acquisition costs	$ (192)	$ (280)	(384)	$ (620)
Ending balance	1,583		1,583
Deferred contract acquisition costs, current (to be amortized in next 12 months)	841		841		$ 768
Deferred contract acquisition costs, non-current	742		742		986
Total deferred contract acquisition costs	$ 1,583		$ 1,583		$ 1,754

Finance leases and other debt -

Finance leases and other debt - Schedule of Outstanding Finance Lease Liabilities and Other Debt (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Debt Instrument [Line Items]
Finance leases	$ 11,858	$ 8,309
Debt	2,600
Total finance lease liabilities and other debt	14,458	11,456
Less: current portion of finance lease liabilities and other debt	(7,161)	(6,056)
Long-term finance lease liabilities and other debt	7,297	5,400
Financing arrangements
Debt Instrument [Line Items]
Debt	2,539	3,124
Accrued interest and payments
Debt Instrument [Line Items]
Debt	$ 61	$ 23

Finance leases and other debt_2

Finance leases and other debt - Narrative (Details) - USD ($)		6 Months Ended
	Dec. 04, 2023	Jul. 31, 2024	Jan. 31, 2024	Mar. 28, 2022	Mar. 27, 2022	May 05, 2020	Feb. 28, 2019
Debt Instrument [Line Items]
Debt		$ 2,600,000
Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount							$ 20,000,000
Financing arrangements
Debt Instrument [Line Items]
Debt		2,539,000	$ 3,124,000
Debt instrument, monthly payment		$ 123,000
Debt instrument, term		36 months
Effective interest rate (as a percent)		10.50%
Revolving Credit Facility | Second SVB Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 50,000,000
Revolving Credit Facility | Third SVB Facility
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 100,000,000	$ 50,000,000
Stated interest rate (as a percent)		3.25%
Scheduled reduction in interest rate (as a percent)		0.50%
Annual fee amount		$ 250,000
Quarterly fee (as a percent)		0.15%
Line of Credit | Senior Secured Asset-based Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term	5 years
Maximum borrowing capacity	$ 50,000
Quarterly fee (as a percent)	0.25%
Effective interest rate (as a percent)		8.40%
Debt issuance costs	$ 778,000
Line of Credit | Senior Secured Asset-based Revolving Credit Facility | Bridge Loan
Debt Instrument [Line Items]
Maximum borrowing capacity	5,000
Line of Credit | Senior Secured Asset-based Revolving Credit Facility | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 5,000

Finance leases and other debt_3

Finance leases and other debt - Schedule of Maturities of Finance Leases and Other Debt (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Total
2025 (Remaining six months)	$ 4,006
2026	6,456
2027	3,580
2028	416
2029	0
Total maturities of finance leases and other debt	14,458
Finance Leases
2025 (Remaining six months)	3,455
2026	5,126
2027	2,861
2028	416
2029	0
Total maturities of finance leases and other debt	11,858	$ 8,309
Other Debt
2025 (Remaining six months)	551
2026	1,330
2027	719
2028	0
2029	0
Total maturities of finance leases and other debt	$ 2,600

Finance leases and other debt_4

Finance leases and other debt - Schedule of Components of Interest Income (Expense), Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Debt Disclosure [Abstract]
Interest expense	$ (608)	$ (420)	$ (1,161)	$ (713)
Interest income	654	1,206	1,446	2,217
Interest income, net	$ 46	$ 786	$ 285	$ 1,504

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($)			6 Months Ended
	Aug. 11, 2023	Jun. 30, 2023	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024	Jan. 30, 2024	Jul. 31, 2023	Apr. 30, 2023	Jan. 31, 2023	Jul. 22, 2019
Class of Stock [Line Items]
Common stock, authorized (in shares)			500,000,000		500,000,000					500,000,000
Common stock, par value per share (in dollars per share)			$ 0.01		$ 0.01					$ 0.01
Shares withheld for tax withholding obligation (in shares)			0
Equity attributable to parent			$ 251,335,000	$ 252,742,000	$ 251,449,000		$ 247,020,000	$ 263,611,000	$ 287,819,000
Amounts reclassified from accumulated other comprehensive income			0
Common Stock
Class of Stock [Line Items]
Equity attributable to parent			591,000	587,000	577,000		554,000	548,000	542,000
Accumulated other comprehensive loss
Class of Stock [Line Items]
Equity attributable to parent			$ (2,000)	$ 1,000	$ 0	$ 0	$ 0	$ 0	$ 0
MediFind
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)		$ 0.01
MediFind | Common Stock
Class of Stock [Line Items]
Business acquisition, shares (in shares)		150,786
Access
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)	$ 0.01
Access | Common Stock
Class of Stock [Line Items]
Business acquisition, shares (in shares)	1,096,436

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Apr. 30, 2024	Jul. 31, 2024
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 252,742	$ 251,449	$ 251,449
Other comprehensive loss	(3)	1
Ending balance	251,335	252,742	251,335
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		0	0
Other comprehensive loss			(2)
Ending balance	(2)		(2)
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	1	0	0
Other comprehensive loss	(3)	1	(2)
Ending balance	$ (2)	$ 1	$ (2)

Equity-based compensation - Nar

Equity-based compensation - Narrative (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2019 shares	Jul. 31, 2024 USD ($) shares	Jul. 31, 2023 USD ($) shares	Jul. 31, 2024 USD ($) offering_period shares	Jul. 31, 2023 USD ($) shares	Jan. 31, 2024 USD ($)	Jan. 31, 2018 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercises in period, intrinsic value | $				$ 2,165,000	$ 4,214,000
Minimum shares earned, minimum target percentage		60%		60%
Maximum shares earned, minimum target percentage		90%		90%
Issuance of common stock for employee stock purchase plan | $		$ 1,608,000	$ 1,838,000
Share settled bonuses | $				$ 6,218,000
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock for employee stock purchase plan (in shares)		89,220	70,123	89,220
Issuance of common stock for employee stock purchase plan | $		$ 1,000	$ 1,000
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee purchase price of common stock (as a percent)				85%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reduced stock compensation expense | $				$ 1,203,000
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, employee common stock purchase discount (as a percent)				15%
Unrecognized compensation costs | $		399,000		$ 399,000
Weighted average remaining expense term (in years)				5 months
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				4 years
Awards vested during period (in shares)				1,156,560
Unrecognized compensation costs | $		87,209,000		$ 87,209,000
Weighted average remaining expense term (in years)				2 years 6 months
Bonus settlement in shares (as a percent)				115%
Restricted stock units | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				1 year
Annual vesting rate (as a percent)				10%
Restricted stock units | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				2 years
Annual vesting rate (as a percent)				20%
Restricted stock units | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				3 years
Annual vesting rate (as a percent)				30%
Restricted stock units | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				4 years
Annual vesting rate (as a percent)				40%
Immediately Vested Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vested during period (in shares)				285,279
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				4 years
Maximum term (in years)				10 years
Unrecognized compensation cost | $		0		$ 0		$ 0
Performance stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				3 years
Annual vesting rate (as a percent)				100%
Awards vested during period (in shares)				0
Unrecognized compensation costs | $		$ 22,802,000		$ 22,802,000
Weighted average remaining expense term (in years)				2 years 2 months 12 days
Performance stock units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual vesting rate (as a percent)				0%
Performance stock units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual vesting rate (as a percent)				220%
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award, number of shares authorized (in shares)							3,048,490
2019 Stock Option and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares)	2,139,683
Percentage increase in number of shares reserved (as a percent)	5%
2019 Stock Option and Incentive Plan | Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares)	855,873
Number of shares available for grant (in shares)		6,269,312		6,269,312
Additional shares authorized (in shares)				338,064
ESPP, number of offering periods per year | offering_period				2
ESPP offering period (in months)				6 months
2019 Stock Option and Incentive Plan | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding shares (in shares)		16,210		16,210
2019 Stock Option and Incentive Plan | Stock Options | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				1 year
Annual vesting rate (as a percent)				25%
2019 Stock Option and Incentive Plan | Stock Options | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				1 year
Annual vesting rate (as a percent)				25%
2019 Stock Option and Incentive Plan | Stock Options | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				1 year
Annual vesting rate (as a percent)				25%
2019 Stock Option and Incentive Plan | Stock Options | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)				1 year
Annual vesting rate (as a percent)				25%
2023 Stock Option And Inducement Plan | Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares)			500,000		500,000
Inducement Plan | Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)		483,790		483,790

Equity-based compensation - Sch

Equity-based compensation - Schedule of Stock - Based Compensation by Type of Award (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 16,763	$ 19,025	$ 33,951	$ 36,500
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	10,960	13,703	22,283	26,602
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	3,483	2,751	6,287	4,395
Liability awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	2,024	2,278	4,721	4,803
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	294	286	658	655
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 2	$ 7	$ 2	$ 45

Equity-based compensation - S_2

Equity-based compensation - Schedule of Stock-Based Compensation in Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 16,763	$ 19,025	$ 33,951	$ 36,500
Less: stock-based compensation expense capitalized as internal-use software	(315)	(377)	(663)	(714)
Stock-based compensation expense per consolidated statements of operations	16,448	18,648	33,288	35,786
Equity Based Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	14,739	16,747	29,230	31,697
Liability Based Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 2,024	$ 2,278	$ 4,721	$ 4,803

Equity-based compensation - S_3

Equity-based compensation - Schedule of Restricted Stock Unit Activity and Market-Based Performance Stock Unit Activity (Details)	6 Months Ended
	Jul. 31, 2024 shares
Restricted stock units
Restricted Stock and Performance Stock Activity [Roll Forward]
Beginning balance (in shares)	3,800,210
Granted (in shares)	1,034,258
Vested (in shares)	(1,156,560)
Forfeited and expired (in shares)	(170,430)
Ending balance (in shares)	3,507,478
Restricted stock units | 2023 Stock Option And Inducement Plan
Restricted Stock and Performance Stock Activity [Roll Forward]
Granted (in shares)	16,210
Performance stock units
Restricted Stock and Performance Stock Activity [Roll Forward]
Beginning balance (in shares)	1,040,219
Granted (in shares)	0
Vested (in shares)	0
Forfeited and expired (in shares)	(14,248)
Ending balance (in shares)	1,025,971

Equity-based compensation - S_4

Equity-based compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jul. 31, 2024
Number of options
Number of options outstanding, beginning (in shares)	1,123,438
Granted (in shares)	0
Exercised (in shares)	(118,153)
Forfeited and expired (in shares)	(3,534)
Number of options outstanding, ending (in shares)	1,001,751
Exercisable (in shares)	1,001,751
Weighted- average exercise price
Weighted- average exercise price outstanding, beginning balance (in dollars per share)	$ 6.89
Granted (in dollars per share)	0
Exercised (in dollars per share)	4.79
Forfeited and expired (in dollars per share)	20.67
Weighted- average exercise price outstanding, ending balance (in dollars per share)	7.09
Exercisable (in dollars per share)	$ 7.09
Outstanding and expected to vest- end of the period (in years)	4 years 18 days
Exercisable- end of period (in years)	4 years 18 days
Aggregate intrinsic value outstanding and expected to vest	$ 17,902
Aggregate intrinsic value exercisable	$ 17,902

Fair value measurements (Detail

Fair value measurements (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	$ 68,165	$ 58,942
Total assets	68,165	58,942
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	68,165	58,942
Total assets	68,165	58,942
Significant Other Observable Inputs (Level 2)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Total assets	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Total assets	$ 0	$ 0

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term (in years)	2 years 1 month 6 days		2 years 1 month 6 days
Operating lease, weighted average discount rate (as a percent)	7.90%		7.90%
Finance lease, weighted average remaining lease term (in years)	2 years 1 month 6 days		2 years 1 month 6 days
Finance lease, weighted average discount rate (as a percent)	7.60%		7.60%
Computer Equipment
Lessee, Lease, Description [Line Items]
Lessee, finance lease, lease not yet commenced, undiscounted payments	$ 7,408		$ 7,408
Subscription and Related Services
Lessee, Lease, Description [Line Items]
Lease income	$ 2,324	$ 2,603	$ 4,712	$ 5,265
Computer Equipment
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	3 years		3 years
Computer Equipment | Minimum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	2 years		2 years
Computer Equipment | Maximum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	3 years		3 years

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Details) $ in Thousands	6 Months Ended
	Jul. 31, 2024 USD ($)
Operating leases:
Operating lease cost	$ 439
Variable lease cost	0
Total operating lease cost	439
Finance leases:
Amortization of right-of-use assets	3,378
Interest on lease liabilities	409
Total finance lease cost	$ 3,787

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating and Finance Leases (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024
Operating
2025 (remaining six months)	$ 568
2026	1,053
2027	583
2028	34
Thereafter	0
Total future minimum lease payments	2,238
Less: interest	(174)
Present value of lease liabilities	2,064
Finance
2025 (Remaining six months)	3,761
2026	5,580
2027	3,114
2028	453
Thereafter	0
Total future minimum lease payments	12,908
Less: interest	(1,050)
Present value of lease liabilities	$ 11,858	$ 8,309

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases			$ 498
Operating cash used for finance leases			409
Financing cash used for finance leases	$ 1,995	$ 1,983	3,275	$ 3,427
Right-of-use assets obtained in exchange for lease liabilities:
Operating	$ 1,194	$ 0	1,958	$ 0
Finance			6,862
Total			$ 8,820

Commitments and contingencies (

Commitments and contingencies (Details) $ in Thousands	Jul. 31, 2024 USD ($) purchase_agreement	Jan. 31, 2024 USD ($)
Loss Contingencies [Line Items]
Purchase commitment non cancelable | purchase_agreement	2
Finance Lease, Computer Equipment, Lease Not yet Commenced
Loss Contingencies [Line Items]
Unrecorded unconditional purchase obligation	$ 7,408
Capital Addition Purchase Commitments
Loss Contingencies [Line Items]
Unrecorded unconditional purchase obligation	$ 9,594
Financing Lease, Lease Not yet Commenced
Loss Contingencies [Line Items]
Unrecorded unconditional purchase obligation		$ 7,413

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Income Tax Disclosure [Abstract]
Income tax provision	$ 750	$ 648	$ 1,260	$ 954
Effective tax rate (as a percent)			3.50%	1.30%

Net loss per share attributab_3

Net loss per share attributable to common stockholders - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jul. 31, 2024	Apr. 30, 2024	Jul. 31, 2023	Apr. 30, 2023	Jul. 31, 2024	Jul. 31, 2023
Numerator:
Net loss	$ (18,012)	$ (19,722)	$ (36,767)	$ (37,531)	$ (37,734)	$ (74,298)
Denominator:
Weighted-average shares of common stock outstanding, basic (in shares)	57,502,959		53,794,060		57,089,232	53,574,584
Weighted-average shares of common stock outstanding, diluted (in shares)	57,502,959		53,794,060		57,089,232	53,574,584
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.31)		$ (0.68)		$ (0.66)	$ (1.39)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.31)		$ (0.68)		$ (0.66)	$ (1.39)

Net loss per share attributab_4

Net loss per share attributable to common stockholders - Schedule of Shares Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,877,852	7,240,405
Stock options to purchase common stock, restricted stock and performance stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,795,068	7,167,904
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	82,784	72,501

Related party transactions (Det

Related party transactions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Jan. 31, 2024
Related Party Transaction [Line Items]
Revenues	$ 102,115	$ 85,830	$ 203,332	$ 169,675
Accounts receivable	61,274		61,274		$ 64,863
General and administrative	19,497	20,988	38,549	40,865
Related Party
Related Party Transaction [Line Items]
Revenues	343	$ 261	671	549
Accounts receivable	$ 116		$ 116		$ 416
General and administrative				$ 118

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - MediFind - USD ($) $ in Thousands		6 Months Ended
	Jun. 30, 2023	Jul. 31, 2023
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)	100%
Total consideration transferred	$ 8,871
Weighted average amortization period (in years)	10 years
Acquisition related costs		$ 699
Common Stock
Business Acquisition [Line Items]
Business acquisition, shares (in shares)	150,786

Acquisitions - Schedule of Medi

Acquisitions - Schedule of MediFind Purchase Price Consideration (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Business Acquisition [Line Items]
Equity consideration paid to sellers		$ 0	$ 4,676	$ 0	$ 4,676
MediFind
Business Acquisition [Line Items]
Cash consideration paid to sellers	$ 4,104		$ 4,104		$ 4,104
Equity consideration paid to sellers	4,676
Liabilities incurred to sellers	91
Total fair value of acquisition consideration	$ 8,871

Acquisitions - Schedule of Cons

Acquisitions - Schedule of Consideration Paid (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Business Acquisition [Line Items]
Cash paid for MediFind Acquisition net of cash acquired per statement of cash flows		$ 0	$ 3,873	$ 0	$ 3,873
MediFind
Business Acquisition [Line Items]
Cash consideration paid to sellers	$ 4,104		4,104		4,104
Less: Cash acquired			(231)		(231)
Cash paid for MediFind Acquisition net of cash acquired per statement of cash flows			$ 3,873		$ 3,873

Acquisitions - Schedule of Allo

Acquisitions - Schedule of Allocation of Purchase Price of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jan. 31, 2024	Jun. 30, 2023
Business Acquisition [Line Items]
Goodwill	$ 75,845	$ 75,845
MediFind
Business Acquisition [Line Items]
Cash			$ 231
Accounts receivable			149
Other current assets			722
Identified intangible assets acquired			2,300
Goodwill			6,821
Total assets acquired			10,223
Accounts payable			(121)
Accrued liabilities			(816)
Deferred revenue			(292)
Deferred income tax liabilities			(123)
Total purchase price			$ 8,871

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Asset Acquired Related to MediFind Acquisition (Details) - USD ($) $ in Thousands	Jul. 31, 2024	Jun. 30, 2023
Trademark
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	15 years
MediFind
Acquired Finite-Lived Intangible Assets [Line Items]
Total identifiable intangible assets acquired		$ 2,300
MediFind | Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)		7 years
Total identifiable intangible assets acquired		$ 1,200
MediFind | Trademark
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)		15 years
Total identifiable intangible assets acquired		$ 700
MediFind | Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)		10 years
Total identifiable intangible assets acquired		$ 400